Second-line treatment for malignant pleural mesothelioma
Authors:
- Giovanni Luca CeresoliGiovanni Luca Ceresoli
- Paolo Andrea ZucaliPZPaolo Andrea Zucali
- Letizia GianoncelliLGLetizia Gianoncelli
- Elena LorenziELElena Lorenzi
- Armando SantoroASArmando Santoro
- 1 February 2010
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 36 (1) , 24-32
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- EverolimusNature Reviews Drug Discovery, 2009
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2009
- Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational studyJournal of Occupational Medicine and Toxicology, 2008
- Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangementCancer Letters, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedThorax, 2007
- Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasionMolecular Cancer Therapeutics, 2007
- Biology and management of malignant pleural mesotheliomaEuropean Journal of Cancer, 2006
- Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycinCancer, 1984